Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma

16 Jun 2022

Abstract excerpt

Group3 (G3) medulloblastoma (MB) is one of the deadliest forms of the disease for which novel treatment is desperately needed. Here we evaluate ribociclib, a highly selective CDK4/6 inhibitor, with gemcitabine in mouse and human G3MBs. Ribociclib central nervous system (CNS) penetration was assessed by in vivo microdialysis and by IHC and gene expression studies and found to be CNS-penetrant. Tumors from mice...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer-related Molecular Pathways
Share to Lung Cancer Research Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35709750
DOI: 10.1158/1535-7163.mct-21-0598

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination of Ribociclib and Gemcitabine for the Treatment of MedulloblastomaPMID 35709750Read ↗

Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In VivoSemantic proximity Read ↗

Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastomaSemantic proximity Read ↗

Effects of Combination Therapy of a CDK4/6 and MEK Inhibitor in Diffuse Midline Glioma Preclinical ModelsSemantic proximity Read ↗

Musashi-1 regulates cell cycle and confers resistance to cisplatin treatment in Group 3/4 medulloblastomas cellsSemantic proximity Read ↗

Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastomaSemantic proximity Read ↗

Enhancing CDK4/6 inhibitor therapy for medulloblastoma using nanoparticle delivery and scRNA-seq-guided combination with sapanisertibSemantic proximity Read ↗

MiR-584-5p potentiates vincristine and radiation response by inducing spindle defects and DNA damage in medulloblastomaSemantic proximity Read ↗

“PBT-SCREEN”, a high-throughput screening platform to identify new therapeutic agents for Medulloblastoma Group 3Semantic proximity Read ↗

Hidden-driver inference reveals synergistic brain-penetrant therapies for medulloblastomaSemantic proximity Read ↗

Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastomaSemantic proximity Read ↗

Repression of Aurora kinase B prevents growth and tissue invasion in medulloblastomaSemantic proximity Read ↗

Improved therapy for medulloblastoma: targeting hedgehog and PI3K-mTOR signaling pathways in combination with chemotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.